Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy - Beyond the Abstract

We evaluated the prognosis of 357 metastatic RCC patients who received VEGFR-TKI or cytokine as initial systemic therapy in the era of molecular-targeted therapy (MTT) and the clinical usefulness of the JMRC prognostic classification. The present study showed for the first time the prognosis of Japanese patients with metastatic RCC in the era of MTT.

The JMRC prognostic classification had been developed as a clinically available prognostic classification for overall survival in metastatic RCC patients in the cytokine era (Shinohara N, et al. Cancer Sci 2012). From the present study, this classification is also clinically useful as a prognostic model (PFS and OS) in metastatic RCC patients in the era of MTT. We therefore believe that the JMRC prognostic classification would be very important in Asian patients with metastatic RCC.

Written by:
Nobuo Shinohara, MD
Department of Renal and Genitourinary Surgery
Hokkaido University Graduate School of Medicine

AbstractPrognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe